Korro Bio Inc (KRRO) ニュース

Form 8-K - Current report

Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update

KRRO-110 is the first product candidate from Korro’s proprietary RNA editing OPERATM platformInterim readout...

Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form POS AM - Post-Effective amendments for registration statement

Form POS AM - Post-Effective amendments for registration statement

Form S-3 - Registration statement under Securities Act of 1933

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]